This Article Free Full Text (Free PDF) Free References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Schwarz, M. Articles by Buchmann, A. Search for Related Content PubMed PubMed Citation Articles by Schwarz, M. Articles by Buchmann, A. Pubmed/NCBI databases Substance via MeSH Social Bookmarking                         What's this?

Role of Connexin32 and β-Catenin in Tumor Promotion in Mouse Liver

Institut für Pharmakologie und Toxikologie, Universität Tübingen, Tübingen, Germany, michael.schwarz{at}uni-tuebingen.de

Ines Wanke

Institut für Pharmakologie und Toxikologie, Universität Tübingen, Tübingen, Germany

Ulrich Wulbrand

Institut für Pharmakologie und Toxikologie, Universität Tübingen, Tübingen, Germany

Oliver Moennikes

Institut für Pharmakologie und Toxikologie, Universität Tübingen, Tübingen, Germany

Albrecht Buchmann

Institut für Pharmakologie und Toxikologie, Universität Tübingen, Tübingen, Germany

Tumor promoters are nonmutagenic chemicals that increase the probability of cancer by accelerating the clonal expansion of cells transformed during tumor initiation. The molecular mechanisms underlying this process are only partly understood but interference with signaling pathways regulating cell division and/or cell death is likely to be important. Ras- and β-Catenin-dependent signaling is important for both of these processes and ras and β-catenin genes are known mutational targets in mouse hepatocarcinogenesis. About 80% of liver tumors generated in mice by a promotional regimen including phenobarbital (PB) as tumor promoter and N-nitrosodiethylamine (DEN) as initiator showed β-catenin mutations whereas Ha-ras mutations were not detected. By contrast, tumors from mice treated with DEN alone showed a ~30% Ha-ras mutation prevalence but no β-catenin mutations. This result suggests that PB-mediated promotion in mouse liver consists in a positive selection for hepatocytes harboring mutations in β-catenin. The gap junction protein connexin 32 (Cx32) was also found to be involved in tumor promotion by PB because Cx32 gene knockout mice were almost entirely resistent to the promotional effects of the barbiturate. The link between β-catenin-signaling and Cx32-dependent gap junctional intercellular communication, if existent, remains obscure.

Key Words: Mouse hepatocarcinogenesis • tumor promotion • phenobarbital • beta-catenin • Ha-ras • connexin32.

Toxicologic Pathology, Vol. 31, No. 1, 99-102 (2003)
DOI: 10.1080/01926230390173932


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				G. Prost, F. Bernier-Valentin, M. Croset, and B. Rousset Impact of connexin32 deletion on E7 or RET/PTC3 oncogene-driven growth and neoplastic transformation of the thyroid gland Endocr. Relat. Cancer, September 1, 2009; 16(3): 873 - 884. [Abstract] [Full Text] [PDF]

				J. M. Phillips, L. D. Burgoon, and J. I. Goodman Phenobarbital Elicits Unique, Early Changes in the Expression of Hepatic Genes that Affect Critical Pathways in Tumor-Prone B6C3F1 Mice Toxicol. Sci., June 1, 2009; 109(2): 193 - 205. [Abstract] [Full Text] [PDF]